SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at MoonLake Immunotherapeutics

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. (“MoonLake” or the “Company”) (NASDAQ: MLTX).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On September 28, 2025, MoonLake disclosed the 16-week data from its Phase 3 VELA study. The findings indicated that SLK failed to achieve a competitive level of effectiveness when compared to BIMZELX.

In response to this disclosure, MoonLake's stock value collapsed. The price declined by $55.75 per share, an 89.9% loss, to finish the trading day at $6.24 on September 29, 2025.

To learn more about the MoonLake Immunotherapeutics investigation, go to www.faruqilaw.com/MLTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.